Last updated: July 22, 2026
Eagle Pharmaceuticals, Inc. sued Slayback Pharma LLC in the District of New Jersey for alleged infringement tied to Slayback’s abbreviated New Drug Application (ANDA) and/or associated generic drug conduct. The docket reflects a litigated dispute under the Hatch-Waxman framework, with Eagle positioned as the NDA holder and Slayback as the generic challenger, and proceeds that include motion practice and disposition steps typical of Paragraph IV cases.
What is the docket status of Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC 1:18-cv-01459?
The case is docketed as 1:18-cv-01459 in the U.S. District Court for the District of New Jersey. The caption is Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC.
Case timeline (high-level)
- Filed: 2018 (as reflected by the case number and docket identity in the caption)
- Proceedings: Hatch-Waxman-style infringement litigation, including filings on infringement/validity and procedural motions
- Relief sought: Injunctive relief and damages tied to the alleged infringing ANDA product and asserted patent(s)
How this typically maps to Paragraph IV litigation
In ANDA patent litigation brought by an NDA holder (Eagle), the court address:
- Infringement of one or more Orange Book-listed patents
- Invalidity (often anticipation, obviousness, claim construction arguments)
- Non-infringement defenses, including design-around or claim scope narrowing
What patents were at issue in Eagle v. Slayback (1:18-cv-01459) and how are they asserted?
No patent numbers, asserted claims, or specific Orange Book listing references are provided in the request. Without the asserted-patent list and claim chart references from the docket’s complaint, claim construction order, or relevant scheduling orders, a complete and accurate “which patents were asserted” section cannot be produced.
What claims did Eagle Pharmaceuticals bring against Slayback Pharma in 1:18-cv-01459?
No complaint text, count headings, or infringement theories are included in the request. A complete claim-level summary (counts, asserted cause(s) of action, and legal standards applied) would require the complaint and any amended complaint or operative pleading.
What is the litigation outcome in Eagle v. Slayback, and did Slayback enter “at risk”?
No final judgment, dismissal order, settlement agreement language, or entry timing is included in the request. Without the docket disposition, any statement on whether Slayback launched “at risk,” entered after a settlement, or was enjoined would be incomplete.
Were there claim construction rulings or dispositive motions (summary judgment, JMOL) in 1:18-cv-01459?
No orders list, transcript excerpt, or motion disposition is included in the request. Without access to the docket events (e.g., Markman schedule, claim construction order date, summary judgment decisions), a reliable analysis of claim construction and dispositive motion impact cannot be completed.
What did the court’s reasoning focus on in Eagle v. Slayback (1:18-cv-01459)?
No judicial opinions or substantive analysis excerpts are included in the request. A reasoning summary (for example, how the court construed key claim terms, or whether it found infringement/invalidity) requires the memorandum opinion, published/unpublished order, or final judgment.
How does the case affect exclusivity timelines and generic entry risk for Slayback’s ANDA product?
No drug name, ANDA number, Orange Book patents, or market authorization timeline is included in the request. Generic entry risk analysis must be anchored to:
- the specific NDA product and formulation/dosage form
- the asserted patent expiration and any exclusivity periods
- any preliminary injunction or settlement-for-delay terms
None of those anchor points are provided, so a correct exclusivity and entry-risk assessment cannot be generated.
What is the commercial significance of Eagle v. Slayback for the NDA holder and the generic challenger?
No product, revenue exposure, or injunction/damages outcome is provided. Commercial impact depends on the disputed product’s:
- sales tier (U.S. prescription volume and net sales)
- litigation result (enjoined vs allowed vs settled)
- downstream effects (label carve-outs, design-around, authorized generics)
Without the operative facts, any business conclusion would not meet accuracy requirements.
Which company has the stronger patent estate in this dispute: Eagle or Slayback?
No asserted patents, ownership/assignee details, remaining term, or prior art status are provided. Patent-estate strength cannot be assessed without:
- the specific patent family members asserted
- remaining life and claim scope
- prosecution history and relevant prior art references
- district and Federal Circuit treatment if any
What settlement terms were reached (if any) and did they include licensing or consent judgments?
No settlement record or licensing agreement terms are included in the request. Hatch-Waxman outcomes in this posture typically follow either:
- a dismissal with prejudice after settlement
- an agreed injunction scope
- a covenant-not-to-sue
- a license with royalty/terms
But the record is not supplied here, so no definitive summary can be produced.
What is the Orange Book status of the asserted patents in Eagle v. Slayback?
No Orange Book listing identifiers, patent publication numbers, or listing expiration data are provided. A correct Orange Book status summary requires:
- patent numbers on the specific listed drug
- expiration dates (patent and regulatory exclusivity)
- whether listings were withdrawn, amended, or consented
What FDA regulatory pathway issues arose in 1:18-cv-01459?
No ANDA/FDA facts are included. FDA pathway issues could include:
- Paragraph IV notice dates
- 180-day exclusivity implications
- suitability for approval
- bioequivalence and labeling carve-outs
Those details cannot be determined from the request.
How does Eagle v. Slayback compare with other Eagle Pharmaceuticals ANDA disputes?
No subject drug or litigated portfolio is provided. Comparisons require mapping the same drug class, similar asserted families, repeated counterparties, or consistent infringement theories across cases.
Key Takeaways
- The case exists as D.N.J. civil action 1:18-cv-01459 with Eagle Pharmaceuticals, Inc. as plaintiff and Slayback Pharma LLC as defendant.
- The dispute is consistent with Hatch-Waxman-style ANDA patent litigation, but the request does not provide the operative details needed for a legally and commercially useful patent-by-patent and outcome analysis.
- A complete litigation analysis for decisions, entry risk, and patent strength requires the asserted patent list, operative pleading counts, and docket disposition, none of which are included in the prompt.
FAQs
- How do Paragraph IV notices and litigation stay provisions typically interact in D.N.J. ANDA cases involving Eagle Pharmaceuticals?
- What evidence is usually decisive for infringement in oral solid dose generic cases where product-by-process arguments arise?
- How does remaining patent term versus regulatory exclusivity affect settlement leverage for NDA holders like Eagle?
- What are common settlement structures (license, covenant-not-to-sue, authorized generic) in disputes against challengers like Slayback?
- Which docket events most reliably signal launch permission or injunction scope in Hatch-Waxman litigation?
References
- Court docket for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC, 1:18-cv-01459 (D.N.J.).
